MaxVal combines strong business and domain knowledge and automated processes to deliver high quality, cost-effective patent related service solutions to clients.
Monday, September 24, 2012
Oracle (plaintiff) filed a complaint for declaratory judgment against Advanced Dynamic Interfaces (ADI) (defendant) on Tuesday, September 18, 2012 in the U.S. Court of Delaware (case no. 1:12-cv-01154).
Oracle is a computer technology corporation that specializes in developing and marketing computer hardware systems and enterprise software products – particularly database management systems. The patents involved in this suit are currently assigned to ADI and are listed below:
Automated generation of dynamic data
entry user interface for relational database management systems
Assignment Alerts are automated email alerts sent to you when assignments
relating to target applications/patents/entities of interest are recorded.
According to this complaint, the suit is filed to protect Oracle’s software Application Express (APEX) from ADI’s statements that APEX infringes the patents-in-suit. APEX is a rapid web application development tool for the Oracle database, allowing customers to develop and deploy professional, fast, and secure applications with only a web browser and limited programming experience.
On July 20, 2012, ADI filed APEX Customer Suit (case no. 1:12-cv-00963) alleging that 20 different companies infringe the ‘502 and ‘094 patents-in-suit, directly and indirectly, through their involvement with Oracle’s APEX and contends that APEX software itself infringes. But ADI did not include Oracle as a defendant even though Oracle owns APEX software. The APEX Customer Suit has triggered indemnity requests by some APEX customers. Oracle denies that the patents-in-suit are infringed through development of APEX software or its use by its customers.
Oracle files this declaratory suit to free its APEX customers and its APEX software from unwarranted allegations of infringement. Oracle further contends that the patents-in-suit are invalid.